Abbvie Inc.

Samuel Kyeremateng

Yi Gao

Nancy E Sever

Ping Tong

Ulrich Westedt

Ute Lander

Harald Hach

Adivaraha Jayasankar

Colleen Garrett

Constanze Obermiller

Katrin Schneider

Michael Simon

Benedikt Steitz

Marius Naris

Regina Reul

Katharina Asmus

Thomas Mueller

Donghua Zhu

Michael Siimon

The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Solid pharmaceutical compositions for treating HCV

Growing community of inventors

Mannheim, Germany

Samuel Kyeremateng